Eight disclosed assets.
Eight independent businesses.
A non-confidential comparison of what each programme addresses, why it is differentiated, what is already under way and where capital or strategic collaboration can accelerate value.
Every asset answers a different need and investment thesis.
The portfolio shows why each product is needed, what it is designed to do, the concrete basis already established and the active programme that capital or strategic collaboration can accelerate.
| Asset | Need and product function | Concrete basis | Active programme / acceleration point |
|---|---|---|---|
| QW-ORL-01 | Prolonged local mucosal contact for recurrent aphthae, oral ulcerations, Candida-related imbalance and VSC-associated halitosis. | Defined mucoadhesive formula, Italian patent filing, manufacturing instructions and quality-control plan. | Pilot-manufacturing and performance-verification activities are under way; capital accelerates stability work and manufacturing transfer. |
| QW-HGL-01 | Integrated support for the gut–liver axis, normal liver function and metabolic detoxification pathways. | Quantitative formula, technical development plan and Italian patent filing. | Pilot definition and industrial-feasibility work are progressing; analytical confirmation and stability are the acceleration points. |
| QW-MET-01 | Metabolic support for prediabetes and type 2 diabetes pathways involving glucose, weight and the microbiome. | Defined botanical and pasteurised Akkermansia architecture, Italian patent filing and manufacturing pathway. | Specialist sourcing and pilot/manufacturing development are under way; capital accelerates analytical work and positioning validation. |
| QW-CPX-01 | Local cosmetic comfort, massage, hydration and barrier support in arthrosis- and arthritis-related areas. | Defined lamellar botanical formula, Italian patent filing, master formula, completed initial pilot batch and QC framework. | Industrial transfer, stability, microbiology, packaging and manufacturing qualification are under way following the initial pilot. |
| QW-RVVC-01 | Oral intestinal and urogenital microbiome support for women affected by recurrent vulvovaginal Candida-related imbalance. | Defined formulation framework and detailed manufacturing-feasibility plan. | Pilot preparation, supplier qualification and IP assessment are progressing; viability, capsule performance and stability are the next acceleration points. |
| QW-POI-01 | Locally administered, age-appropriate galenic ophthalmic solution for selected ocular needs. | Defined unmet-need rationale, initial concept and mapped development questions. | Formulation and feasibility development are active; specialist collaboration accelerates tolerability assessment and the pharmaceutical development map. |
| QW-AF-01 | Finished multicomponent botanical cream advanced through dedicated Candida albicans research and testing. | Finished formulation platform, historical documentation and preliminary microbiological work. | Targeted testing and the industrial pathway are active; quantitative and possible biofilm work, IP, classification and regulation can be accelerated. |
| QW-HSV-01 | New non-acyclovir topical formulation for recurrent genital herpes and future pharmaceutical progression. | Approximately ten years of historical formulation experience, use knowledge and technical development foundation. | Final formulation and new-patent development are active; pilot, analytical and stability activities follow the defined formula. |
Preliminary overview
Market need, project rationale, intended product category and general route to market.
Qualified counterparties
Technical packages, intellectual-property documentation and development records after an appropriate review process.
Defined separately
Rights, company structure, funding terms and milestones are established for each selected opportunity.
Commercially relevant starting volumes.
For selected products, manufacturing scenarios are being defined according to product format, validation status and qualified manufacturer requirements. The objective is to support controlled initial production and a credible route to commercial scale after the required validation, regulatory and manufacturing steps are completed.
Substance before publicity.
Commercial names, trademark candidates, confidential formulations, technical percentages and unpublished know-how are not disclosed publicly. Public descriptions focus on the investment-relevant facts; detailed evidence, formulations, development data and regulatory strategy are available through the protected qualification process.